Latest updates on ABL’s HIV Assays Portfolio

ABL is delighted to announce the outcomes of a National Quality Control Study performed on the DeepChek® HIV Assays (RT/PR and INTEGRASE) on a panel human plasma samples collected in 2015 in 56 different labs in France. The overall agreement in the detection of HIV virus mutations exceeded 99% compared to the expected results with a 100% sensitivity (percentage of positions defined as mutated among real mutated positions) and a specificity (percentage of positions defined as “wild-type” compared to real “wild-type” positions) >99%. Those assays combine target-specific PCR reagents with in vitro diagnostic software both compatible with either Sanger or Next Generation Sequencing platforms for HIV genotyping.
In addition to its DeepChek® Assays, ABL is pleased to announce the release of a new line of molecular biology products, called UltraGene-HIV, during the second quarter of 2017, intended to be primarily used for HIV viruses’ viral load detection and which can also be used for genotyping through Next Generation Sequencing.
Please contact us ( for more information.
About ABL
Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC™ and the DPM which are used for data and patient management, monitoring and personalized reporting applications. In 2012, some of ABL’s products also received CE-marking for IVD use. ABL’s products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions for sequencing, clinical genotyping and drug resistance analysis, including powerful fully integrated databases and analysis systems that combine standard and high-throughput Next Generation Sequencing data. ABL’s DeepChek® SingleRound HIV and Hepatitis C Virus (HCV) Genotyping and Sequencing assays are the first two in its virology reagents portfolio. These are currently available for Research Use Only.